Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sotera Health (SHC) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Sotera Health (SHC) over the last 6 years, with Q3 2025 value amounting to $299.2 million.

  • Sotera Health's Cash & Equivalents fell 246.01% to $299.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.2 million, marking a year-over-year decrease of 246.01%. This contributed to the annual value of $277.2 million for FY2024, which is 646.58% down from last year.
  • Latest data reveals that Sotera Health reported Cash & Equivalents of $299.2 million as of Q3 2025, which was down 246.01% from $332.4 million recorded in Q2 2025.
  • In the past 5 years, Sotera Health's Cash & Equivalents ranged from a high of $647.9 million in Q1 2023 and a low of $106.9 million during Q4 2021
  • For the 5-year period, Sotera Health's Cash & Equivalents averaged around $251.9 million, with its median value being $261.1 million (2024).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 43355.4% in 2023, then tumbled by 5969.85% in 2024.
  • Quarter analysis of 5 years shows Sotera Health's Cash & Equivalents stood at $106.9 million in 2021, then surged by 269.65% to $395.2 million in 2022, then decreased by 25.0% to $296.4 million in 2023, then fell by 6.47% to $277.2 million in 2024, then increased by 7.92% to $299.2 million in 2025.
  • Its Cash & Equivalents stands at $299.2 million for Q3 2025, versus $332.4 million for Q2 2025 and $304.4 million for Q1 2025.